ASH 2014: High Hodgkin's lymphoma responses for BMS, Merck PD-1 inhibitors
This article was originally published in Scrip
Executive Summary
The race between programmed cell death-1 (PD-1) immune checkpoint inhibitors from Bristol-Myers Squibb and Merck & Co continues with promising data for both monoclonal antibodies in Hodgkin's lymphoma, but Bristol-Myers's Opdivo (nivolumab) has an overall response rate (ORR) edge over Merck's Keytruda (pembrolizumab).